Back to Search
Start Over
A novel flavonoid C-glucoside from Ulmus wallichiana preserves bone mineral density, microarchitecture and biomechanical properties in the presence of glucocorticoid by promoting osteoblast survival: a comparative study with human parathyroid hormone.
- Source :
-
Phytomedicine : international journal of phytotherapy and phytopharmacology [Phytomedicine] 2013 Nov 15; Vol. 20 (14), pp. 1256-66. Date of Electronic Publication: 2013 Aug 06. - Publication Year :
- 2013
-
Abstract
- Purpose: 6-C-β-D-glucopyranosyl-(2S,3S)-(+)-5,7,3',4'-tetrahydroxydihydroflavonol (GTDF) is a novel compound isolated from Ulmus wallichiana, reported to have bone anabolic action in ovariectomized rats. Here, we studied the effect of GTDF in glucocorticoid (GC)-induced bone loss and its mode of action.<br />Methods: Osteoblasts were cultured from rat calvaria or bone marrow to study apoptosis and differentiation by dexamethasone (Dex), methylprednisolone (MP), GTDF, quercetin and rutin. Female Sprague Dawley rats were treated with Dex or MP with or without GTDF or PTH. Efficacy was evaluated by bone microarchitecture using microcomputed tomography, determination of new bone formation by fluorescent labeling of bone and osteoblast apoptosis by co-labeling bone sections with Runx-2 and TUNEL. Serum osteocalcin was determined by ELISA.<br />Results: GTDF preserved trabecular and cortical bones in the presence of Dex and MP and mitigated the MP-mediated suppression of serum osteocalcin. Co-administration of GTDF to MP rats increased mineral apposition, bone formation rates, bone biomechanical strength, reduced osteoblast apoptosis and increased osteogenic differentiation of bone marrow stromal cells compared to MP group, suggesting in vivo osteogenic effect of GTDF. These effects of GTDF were to a great extent comparable to PTH. GTDF prevented GC-induced osteoblast apoptosis by inhibiting p53 expression and acetylation, and activation of AKT but did not influence transactivation of GC receptor (GR).<br />Conclusions: GTDF protects against GC-induced bone loss by promoting osteoblast survival through p53 inhibition and activation of AKT pathways but not as a GR antagonist. GTDF has the potential in the management of GC-induced osteopenia.<br /> (Copyright © 2013 Elsevier GmbH. All rights reserved.)
- Subjects :
- Animals
Apoptosis drug effects
Biomechanical Phenomena
Bone and Bones metabolism
Female
Flavonols isolation & purification
Flavonols pharmacology
Glucosides isolation & purification
Glucosides pharmacology
Glucosides therapeutic use
Male
Mesenchymal Stem Cells drug effects
Osteocalcin blood
Osteoporosis blood
Osteoporosis chemically induced
Parathyroid Hormone metabolism
Parathyroid Hormone pharmacology
Phytotherapy
Plant Extracts isolation & purification
Plant Extracts pharmacology
Plant Extracts therapeutic use
Proto-Oncogene Proteins c-akt metabolism
Rats
Rats, Sprague-Dawley
Tumor Suppressor Protein p53 metabolism
Bone Density drug effects
Bone and Bones drug effects
Flavonols therapeutic use
Glucocorticoids adverse effects
Osteoblasts drug effects
Osteogenesis drug effects
Osteoporosis prevention & control
Ulmus chemistry
Subjects
Details
- Language :
- English
- ISSN :
- 1618-095X
- Volume :
- 20
- Issue :
- 14
- Database :
- MEDLINE
- Journal :
- Phytomedicine : international journal of phytotherapy and phytopharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 23928508
- Full Text :
- https://doi.org/10.1016/j.phymed.2013.07.007